5 Key Takeaways

• 1

  Caribou Biosciences plans to discontinue its two allogeneic CAR T-cell programs and substantially reduce its workforce after failing to secure development funding.

• 2

  The company’s board is reviewing strategic alternatives, including a merger, acquisition, business combination, or transaction involving Caribou or its assets.

• 3

  Caribou reported $113.8 million in cash, cash equivalents, and marketable securities on June 30, after previously projecting funds through the end of 2027.

• 4

  Vispa-cel, an anti-CD19 therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, was ready to enter a pivotal phase 3 trial, while CB-011 targets multiple myeloma.

• 5

  The workforce reduction is expected to be largely completed in the fourth quarter of 2026, and CEO Rachel Haurwitz said she hoped another organization would continue the programs.